Not yet recruitingNCT07627620Updated Jun 4, 2026

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

A Phase 2 interventional study of Camrelizumab and Famitinib Malate in Cervical Cancer, sponsored by Hunan Cancer Hospital. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Hunan Cancer Hospital · Phase 2, Interventional, and Treatment

Phase: Phase 2
Study type: Interventional
Enrollment: 54
Allocation: Not applicable
Ages: 18 Years to 75 Years
Sex: Female

Study summary

This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.

Conditions studied

Cervical Cancer

Browse trials for

Uterine Cervical Neoplasms 1,883

Keywords

Cervical Cancer
Chemotherapy
Camrelizumab
Famitinib malate

In context

Uterine Cervical Neoplasms

1,883 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.

This study's planned enrollment of 54 is below the median of 100 across 1,378 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Hunan Cancer Hospital is the lead sponsor of 54 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 75 Years
Sexes eligible: Female
Accepts healthy volunteers: No

Inclusion criteria

Female aged 18-75 years.
Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy.
No prior systemic anti-cancer therapy for recurrent/metastatic disease.
According to RECIST v1.1 criteria, the patient must have at least one measurable lesion.
Able to normally swallow drug tablets
Has adequate organ function.
Willing to participate and able to comply with research programme requirements.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Estimated life expectancy of more than 3 months.

Exclusion criteria

Exclusion Criteria:

Has any malignancy \<5 years prior to study entry.
Known to have brain or meningeal metastasis.
Known to have autoimmune disease.
Received live vaccinations 4 weeks before randomization or during the study period.
Known allergies and contraindications to the investigational drug or any of its components.

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 54 participants (estimated)

Study arms

Experimental
Camrelizumab combined with famitinib malate and chemotherapy
Drug: Camrelizumab · Drug: Famitinib Malate · Drug: Chemotherapy

Interventions

DrugCamrelizumab
Intravenous (IV) on Day 1 of each cycle
DrugFamitinib Malate
Famitinib po qd
DrugChemotherapy
Paclitaxel + cisplatin or carboplatin

What researchers measure

Primary outcomes

Objective response rate (ORR)
Objective Response Rate defined as the percentage of participants who have a complete response or a partial response (PR) per RECIST 1.1.
Time frame: up to 2 years

Secondary outcomes

Disease control rate (DCR)
DCR is defined as the percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.
Time frame: up to 2 years
Duration of response (DOR)
Duration of Response per RECIST 1.1.
Time frame: Up to 2 years
Time to response (TTR)
TTR is defined as the time from the date of first dose until the date of first documented response per RECIST 1.1.
Time frame: up to 2 years
Progression-free survival (PFS)
PFS is defied as time from the date of first dose to first documented of disease progression (RECIST1.1) or date of death.
Time frame: Up to 2 years
Overall Survival (OS)
OS was defined as the time from the date of first dose until death due to any cause.
Time frame: Up to 2 years
Safety
Incidence, type and severity of adverse events
Time frame: Up to 2 years

Study locations

No study locations are listed for this record.

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07627620
Lead sponsor: Hunan Cancer Hospital
Responsible party: Sponsor
First posted: Jun 4, 2026
Start date: Jun 30, 2026 (estimated)
Primary completion: Sep 30, 2027 (estimated)
Completion: Mar 30, 2029 (estimated)
Last update: Jun 4, 2026

Study contacts

Jie Tang

Contact

tangjie@hnca.org.cn

0731-89762071

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Uterine Cervical Neoplasms→

Other studies from this sponsor

Hunan Cancer Hospital

Start the discussion